Literature DB >> 10614781

Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes.

G Cook1, J D Campbell, C E Carr, K S Boyd, I M Franklin.   

Abstract

Multiple myeloma (MM) is a cancer of plasma cells, characterized by profound suppression of host immune responses. Here we show that MM cell lines significantly suppress the proliferation, blasting, response to interleukin-2 (IL-2), and expression of CD25 by concanavalin A (Con A)-activated or allostimulated peripheral blood T lymphocytes. T cells arrest in the G1 stage of the cell cycle, and do not enter the IL-2 autocrine growth pathway. T cell inhibition was mediated by a soluble factor. MM cell lines did not produce IL-10 but did produce large amounts of transforming growth factor beta1 (TGF-beta1). T cells were assessed for their ability to respond to IL-2 when co-cultured with MM cells in the presence or absence of the TGF-beta inhibitor, TGF-beta latency-associated peptide (LAP). MM cells suppressed IL-2 responses but this inhibition was completely reversed by TGF-beta LAP. A CD25-, IL-2-dependent blast cell line was not inhibited by MM cells or rhTGF-beta, confirming the specificity of the inhibition mechanism for the IL-2 autocrine growth pathway. We conclude that MM cells suppress T cells in their entry into the autocrine IL-2/CD25 pathway and in response to IL-2, and that TGF-beta has a significant role to play.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10614781     DOI: 10.1002/jlb.66.6.981

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  24 in total

Review 1.  Reversal of tumor-induced immunosuppression by TGF-beta inhibitors.

Authors:  Slawomir Wojtowicz-Praga
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

2.  Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.

Authors:  A Barber; K R Meehan; C L Sentman
Journal:  Gene Ther       Date:  2011-01-06       Impact factor: 5.250

Review 3.  Clinical Development of PD-1 Blockade in Hematologic Malignancies.

Authors:  Matthew J Pianko; Aaron D Goldberg; Alexander M Lesokhin
Journal:  Cancer J       Date:  2018 Jan/Feb       Impact factor: 3.360

Review 4.  Immune checkpoint blockade for hematologic malignancies: a review.

Authors:  Matthew J Pianko; Yuzhou Liu; Srishti Bagchi; Alexander M Lesokhin
Journal:  Stem Cell Investig       Date:  2017-04-19

5.  Lipoteichoic acid inhibits interleukin-2 (IL-2) function by direct binding to IL-2.

Authors:  L M Plitnick; R A Jordan; J A Banas; D M Jelley-Gibbs; M C Walsh; M T Preissler; E J Gosselin
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

6.  Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.

Authors:  A Busch; D Zeh; V Janzen; L-O Mügge; D Wolf; L Fingerhut; C Hahn-Ast; O Maurer; P Brossart; M von Lilienfeld-Toal
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

7.  Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.

Authors:  R N Pearse; E M Sordillo; S Yaccoby; B R Wong; D F Liau; N Colman; J Michaeli; J Epstein; Y Choi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

8.  The anergic state in sarcoidosis is associated with diminished dendritic cell function.

Authors:  Sneha Mathew; Kristy L Bauer; Arne Fischoeder; Nina Bhardwaj; Stephen J Oliver
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

9.  Down-modulation of lung immune responses by interleukin-10 and transforming growth factor beta (TGF-beta) and analysis of TGF-beta receptors I and II in active tuberculosis.

Authors:  M Glória Bonecini-Almeida; John L Ho; Neio Boéchat; Richard C Huard; Sadhana Chitale; Howard Doo; Jiayuan Geng; Lorena Rego; Luiz Claudio Oliveira Lazzarini; Afrânio L Kritski; Warren D Johnson; Timothy A McCaffrey; José R Lapa e Silva
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

10.  In vivo consequence of vitamin C insufficiency in liver injury: vitamin C ameliorates T-cell-mediated acute liver injury in gulo(-/-) mice.

Authors:  Seyeon Bae; Chung-Hyun Cho; Hyemin Kim; Yejin Kim; Hang-Rae Kim; Young-Il Hwang; Jung Hwan Yoon; Jae Seung Kang; Wang Jae Lee
Journal:  Antioxid Redox Signal       Date:  2013-04-18       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.